Skip Navigation


Issue No. 34 | August 15, 2008
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

Tenofovir Approved for Use in Hepatitis B Patients

"The Food and Drug Administration has approved [the] HIV drug Viread (tenofovir) as a treatment for hepatitis B. The approval was based on two clinical trials demonstrating that Viread is more effective than Hepsera in fighting liver inflammation and scarring caused by chronic hepatitis B infection."

For more information, read the full story.

Circumcision May Be More Protective against HIV than Previously Thought

"Circumcision may offer even more protection against female-to-male HIV transmission than previously revealed, as well as partial protection against human papillomavirus (HPV)."

For more information, read the full story.

Only One Percent of HIV Patients Are Tested for TB

"World Health Organization statistics show that just 314,394 of the 33 million people living with HIV/AIDS globally have been tested for TB. Of those screened, more than one in four were found to have active TB."

For more information, read the full story.

Study on an HIV Elite Suppressor

"The results strongly suggest that through direct and indirect mechanisms, CD8+ T cells in some [elite suppressors] control HIV-1 isolates [and] are capable of causing profound immunosuppression."

For more information, read the full study abstract.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Contact Us
Left footer corner image Left footer corner image